Donald Braun, PhD

Dr. Braun has over 25 years of research experience in immunology, microbiology, inflammatory diseases, oncology, cancer immunology, and cancer immunotherapy. His focus has been on identifying biological and molecular targets intrinsic to cancer disease processes, and applying targeted therapeutics to address those processes.

Dr. Braun has served as an advisor to numerous public agencies concerned with cancer. He served on the Experimental Therapeutics Study Section of the National Cancer Institute, and the Experimental Immunology and Immunotherapy Study Section of the American Cancer Society – National Division. Dr. Braun formerly held the roles of Vice President of Clinical Research at the Cancer Treatment Centers of America (CTCA), overseeing clinical research operations regarding project planning, design, execution, and analysis, and Vice President of Translational Research and Chief Science Officer at CTCA. He has also served as the Administrative Director of the Medical College of Ohio Cancer Institute and as the Scientific Director of Rush Cancer Institute.

Dr. Braun has authored more than 100 published peer-reviewed manuscripts, 20 reviews and book chapters, 130 abstracts, and co-edited one book devoted to the use of prostaglandin inhibitors in cancer immunotherapy.